Su M, Gao Y, Ye X, et al. - Researchers undertook this retrospective analysis to determine the therapeutic utility of apatinib in patients with chemo-refractory advanced cervical cancer. Cases managed with apatinib for advanced cervical cancer at the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, from April 2015 to December 2018, were included if failed at least 2 lines of chemotherapy before receiving apatinib. The study sample included 25 patients. The median progression-free survival and the median overall survival were estimated to be 5.8 months and 12.2 months, respectively. The observed objective response rate and disease control rate were 48% and 96%, respectively. No complete response was achieved. Hand-foot syndrome (48%), hypertension (20%), and mouth mucositis (20%) were documented as the most commonly experienced adverse events. Overall, findings revealed a good therapeutic value of apatinib monotherapy, along with tolerable adverse events associated with it, in patients with chemo-refractory advanced cervical cancer.